Overview: Medical Device Regulation in Uruguay
Uruguay regulates medical devices through the Ministerio de Salud Pública (MSP). The country aligns its framework with MERCOSUR technical regulations, creating increasing harmonization across member states including Brazil, Argentina, and Paraguay.
In 2026, key regulatory priorities include:
- Risk-based classification alignment
- Digitalization of submissions
- Strengthened post-market surveillance
- Phased UDI implementation
- Greater regional harmonization
For manufacturers entering Uruguay or expanding within MERCOSUR, understanding these updates is critical for efficient market access.
Medical Device Classification in Uruguay
Uruguay follows the MERCOSUR four-class risk-based system:
- Class I – Low risk
- Class II – Low to moderate risk
- Class III – Moderate to high risk
- Class IV – High risk
Active implantable devices fall within the highest risk tier under MERCOSUR provisions.
IVD Classification
In Vitro Diagnostic devices follow MERCOSUR’s risk-based framework aligned with international standards, using Classes A through D based on individual and public health risk.
Risk classification determines:
- Technical documentation requirements
- Clinical evidence expectations
- Review depth and timelines
- GMP inspection requirements
- Post-market obligations
Accurate classification is essential before beginning dossier preparation.
Uruguay Medical Device Registration Process
Foreign manufacturers must appoint a locally established Authorized Representative (AR) in Uruguay. The AR holds the registration and is legally responsible for regulatory compliance, vigilance reporting, and communication with MSP.
Step 1: Appoint an Authorized Representative
- Notarized and legalized Power of Attorney
- Local establishment required
Step 2: Prepare the Technical Dossier
Documentation requirements align with MERCOSUR regulations and increasingly reflect structured technical documentation principles similar to STED.
Key components include:
- Administrative forms
- Device description and intended use
- Risk management documentation compliant with ISO 14971
- Verification and validation data
- Clinical evaluation or investigation data where required
- ISO 13485 certificate
- GMP evidence
- Spanish labeling and IFU
Step 3: Submission
Submissions are made via the national single window system (VUCE) or MSP electronic platforms. Uruguay continues transitioning toward greater digital submission capabilities.
Step 4: Regulatory Review
Review timelines vary depending on device class and complexity. Higher-risk devices may require additional technical evaluation.
Step 5: Approval and Registration Certificate
Upon approval, MSP issues a registration certificate.
- Validity: Generally 5 years
- Renewal: Must be filed prior to expiration with updated compliance documentation
Quality Management System (QMS) Requirements
Uruguay recognizes:
- ISO 13485:2016 certification
- MERCOSUR GMP compliance
- GMP certificates from recognized authorities depending on equivalence
MSP may conduct inspections or request additional GMP evidence, particularly for higher-risk devices.
Authorized Representatives are also subject to compliance oversight to ensure:
- Proper import and distribution controls
- Vigilance system management
Complaint handling procedures
UDI Requirements in Uruguay
Uruguay is implementing Unique Device Identification (UDI) in alignment with MERCOSUR Resolution GMC 07/24.
Implementation is phased, beginning with higher-risk devices. Companies should monitor MSP guidance for:
- UDI carrier requirements
- Database submission obligations
- Implementation timelines by device class
Early preparation is recommended to avoid compliance disruptions as enforcement expands.
Post-Market Surveillance and Vigilance
Uruguay has strengthened post-market expectations in recent years.
Manufacturers and Authorized Representatives must:
- Report serious adverse events within regulatory timelines
- Notify MSP prior to executing Field Safety Corrective Actions
- Maintain traceability and distribution records
- Retain documentation for extended retention periods
Non-compliance may result in administrative fines, suspension of registration, or market withdrawal.
Clinical Investigation Requirements
Clinical investigations may be required for:
- Higher-risk devices
- Novel technologies
- Devices lacking sufficient clinical evidence
Requirements include:
- Ethics Committee approval
- Compliance with Good Clinical Practice
- MSP authorization prior to study initiation
- Potential regulatory inspections
Structured clinical evaluation documentation is increasingly expected.
Key Regulatory Trends in 2025–2026
Manufacturers should monitor the following developments:
- Continued MERCOSUR harmonization
- Increased digitalization of regulatory submissions
- Expansion of UDI implementation
- Strengthened post-market oversight
- Alignment with IMDRF risk-based principles
Uruguay remains an important strategic entry point into the MERCOSUR region due to its regulatory predictability and alignment with regional standards.
Strategic Tips for Entering the Uruguay Market
To streamline approval:
- Confirm device classification early
- Select an experienced Authorized Representative
- Prepare Spanish labeling at the outset
- Ensure ISO 13485 certification is current
- Plan ahead for UDI compliance
- Monitor MERCOSUR updates impacting documentation
Companies already operating in Brazil or Argentina may benefit from documentation harmonization efficiencies.
How RegDesk Supports Uruguay and MERCOSUR Compliance
RegDesk is an AI-powered Regulatory Information Management System built for medical device manufacturers operating across global markets.
With RegDesk, teams can:
- Track MSP and MERCOSUR regulatory updates in real time
- Prepare and manage structured technical documentation
- Centralize ISO 13485 and GMP records
- Monitor UDI implementation requirements
- Coordinate LATAM submissions
- Manage post-market surveillance and vigilance reporting
As regulatory frameworks across MERCOSUR continue to align, centralized regulatory intelligence is essential to maintain compliance and accelerate market access.
